Drug-induced gingival enlargement

Lore & Background

Drug-induced gingival enlargement is primarily associated with three classes of drugs: anticonvulsants, immunosuppressive drugs, and calcium channel blockers. Anticonvulsant agents such as phenytoin cause overgrowth through an increase of metabolites from their breakdown in the body. Concurrent usage of different anticonvulsants in children has resulted in accumulative gingival enlargement. Among immunosuppressive drugs, cyclosporin is the most frequently used, with nearly 53% of renal transplant patients on cyclosporin presenting with gingival growth. Its main metabolite, hydroxycyclosporin, stimulates collagen production while inhibiting collagen breakdown, leading to net tissue increase. Tacrolimus is less toxic than cyclosporin, causing less severe gingival overgrowth, hepatic and renal toxicity.

Reader's Guide

Management of drug-induced gingival enlargement begins with proper oral hygiene as the least invasive option. Ceasing the causative medication may be advisable, but only with the patient's medical practitioner's consent, and complete resorption may take up to eight weeks. When medication cannot be paused, replacement drugs such as vigabatrin for phenytoin may be suggested, though this may be ineffective for long-standing overgrowth. Surgical removal via gingivectomy is widely successful, though recurrence has been reported for certain drugs. The procedure carries risk of hemorrhage in highly inflamed and vascularized gingiva, so CO2 laser or ND:YAG laser has been suggested for accurate, cauterized, and sterilized incisions. Nonsurgical interventions such as fast mimicking diet regimes and nonsurgical periodontal therapy have been suggested to alleviate overgrowth and reduce the need for surgery, but they cannot prevent or fully resolve gingival overgrowth alone.

Did You Know?

• Drug-induced gingival enlargement is also called drug-induced gingival hyperplasia or drug-induced gingival overgrowth.
• Nearly 53% of patients taking cyclosporin after renal transplants presented with gingival growth.
• Complete resorption of gingival overgrowth after ceasing medication may take up to 8 weeks.
• Tacrolimus causes less severe gingival overgrowth than cyclosporin.

Terminology and the Five-Group Framework

Gingival enlargement refers to a measurable increase in the size of the gums, a feature frequently encountered in periodontal disease. Historically, clinicians reached for the labels hyperplasia and hypertrophy, but both are strictly histologic diagnoses that demand microscopic examination of a tissue sample. Hyperplasia denotes an increased number of cells, while hypertrophy points to enlarged individual cells. Because neither distinction can be confirmed through a routine clinical inspection, the broader and more accurate term gingival enlargement has become the standard. The condition is further sorted into five causal categories: inflammatory enlargement, drug-induced enlargement, enlargement linked to systemic diseases or conditions, neoplastic enlargement, and false enlargement. A closely related concept is epulis, which specifically describes a localized lump or tumor on the gingiva rather than a diffuse enlargement. Understanding which category a patient falls into is essential, because the treatment pathway shifts dramatically depending on whether the underlying driver is plaque, a medication, a blood disorder, a tumor, or an underlying bony lesion masquerading as gum growth.

Three Drug Families, One Shared Response

Drug-induced gingival enlargement, often abbreviated DIGO, is triggered by three distinct pharmacologic families that nonetheless produce a remarkably similar tissue response. The first and most frequently implicated group is the anticonvulsants, which include phenytoin, phenobarbital, lamotrigine, vigabatrin, ethosuximide, topiramate, and primidone, though valproate is notably absent from the list. The second family comprises calcium channel blockers used as antihypertensives, specifically nifedipine, amlodipine, and verapamil. The third is cyclosporine, an immunosuppressant widely used in transplant medicine. In terms of distribution, roughly half of all DIGO cases trace back to phenytoin, about thirty percent to cyclosporine, and the remaining ten to twenty percent to calcium channel blockers. Researchers have also noted a possible genetic predisposition in affected patients, and the role of pre-existing inflammation remains contested: some investigators argue that inflammation must be present for the drug effect to manifest, while others contend that the drug-driven overgrowth itself worsens plaque retention and amplifies the inflammatory cascade.

The Molecular Engine Behind Fibrotic Overgrowth

At the cellular level, drug-induced gingival overgrowth appears to operate through at least two pathways, one fibrotic and one inflammatory. The fibrotic mechanism centers on a matricellular protein called CTGF, also known as CCN2, which is a well-established driver of fibrosis. TGF-β, a signaling molecule, appears to stimulate the production of CTGF, although the precise molecular steps connecting the two have not yet been fully elucidated. A particularly striking feature of gingival fibroblasts is that their CTGF levels are not suppressed by inflammatory mediators such as prostaglandin E2, a regulatory mechanism that is clearly operative in fibroblasts from other organs like the kidney. This resistance to down-regulation may help explain why gingival tissue is so vulnerable to progressive fibrotic buildup under drug influence. Because TGF-β sits upstream of the CTGF pathway, it has been proposed as a potential therapeutic target for interrupting the cascade. The inflammatory type of overgrowth represents a separate, though possibly overlapping, mechanism that contributes to the overall tissue response.

From Plaque Control to Drug Substitution

Managing drug-induced gingival enlargement follows a stepwise logic that begins with the simplest intervention. The first line of defense is meticulous oral hygiene and plaque control, aimed at stripping away the irritative bacterial biofilm that accumulates around the cervical regions of the teeth and gums. When the overgrowth carries a significant fibrotic component that fails to shrink after conventional scaling and root planing, surgical excision through a gingivectomy becomes the next option. In most DIGO cases, however, the most effective remedy is straightforward: stopping the offending medication or switching to an alternative agent resolves the overgrowth. When discontinuation is not clinically feasible, substitution strategies come into play. For patients on cyclosporine, tacrolimus offers comparable immunosuppressive efficacy with markedly less gingival overgrowth, though it carries a similar nephrotoxic profile. For those taking nifedipine, the dihydropyridine derivative isradipidine can serve as a replacement without triggering the same overgrowth response. Careful attention to daily oral hygiene remains a constant adjunct, as it can meaningfully reduce the severity of the condition regardless of the pharmacologic strategy chosen.